title: Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor.
abstract: Mast cells are involved in the development of psoriatic lesion, but it is not known how mast cells are activated or whether mast cell cytokines are expressed during the lesion development. In this study, the Köbner reaction was induced in uninvolved psoriatic skin of 18 patients using the tape-stripping technique, and a sequence of biopsies was collected at 0 days, 2 h and 3 days or at 0 days, 1 day and 7 days for histochemical analysis. Eight patients developed the Köbner reaction verified at the follow-up visit 2-2·5 weeks later. No significant differences were observed in total tryptase(+)  mast cells, psoriasis area and severity index and age/sex. Instead, the percentage of tryptase(+)  mast cells showing interleukin (IL)-6 immunoreactivity was significantly higher in biopsies from Köbner-positive patients than in those from Köbner-negative patients. IL-33 is a known inducer of IL-6 in mast cells, and the number of IL-33(+)  cells increased significantly in Köbner-positive dermal skin at days 3-7. The number of dermal cells with IL-6 receptor (IL-6R, CD126) also increased in Köbner-positive skin at days 3-7. Unexpectedly, the number of IL-6R(+)  cells was even higher in Köbner-negative skin at days 3-7. In the chronic plaque of 10 other psoriatic patients, the numbers of IL-6(+)  mast cells and dermal cells showing IL-6R were higher than those in the non-lesional skin. In conclusion, the positive Köbner reaction is associated with IL-6 in mast cells and appearance of IL-6R(+)  and IL-33(+)  dermal cells. This suggests that a previously unrecognized vicious circle may develop in the early psoriatic lesion.
authors.affiliation: Department of Dermatology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
authors.forename: M-M
authors.initials: MM
authors.lastname: Suttle
authors.forename: G
authors.initials: G
authors.lastname: Nilsson
authors.forename: E
authors.initials: E
authors.lastname: Snellman
authors.forename: I T
authors.initials: IT
authors.lastname: Harvima
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D002452:Cell Count; D020405:Dermis / Q000378:metabolism / Q000473:pathology*; D004817:Epidermis / Q000293:injuries / Q000378:metabolism / Q000473:pathology*; D004890:Erythema / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D000067596:Interleukin-33; D015850:Interleukin-6 / Q000096:biosynthesis*; D007378:Interleukins / Q000096:biosynthesis*; D008297:Male; D008407:Mast Cells / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D011565:Psoriasis / Q000378:metabolism / Q000473:pathology*; D011897:Random Allocation; D019947:Receptors, Interleukin-6 / Q000096:biosynthesis*; D012720:Severity of Illness Index; D053832:Surgical Tape; D013997:Time Factors
chemical_list: C506536:IL33 protein, human; C508600:IL6 protein, human; D000067596:Interleukin-33; D015850:Interleukin-6; D007378:Interleukins; D019947:Receptors, Interleukin-6